Advertisement
Screener

SCHOLAR ROCK HOLDING CORPORATION (SRRK) Contract Liability (Deferred Revenue)

2.8 / 5 stars · 68/120 Roast Me

SCHOLAR ROCK HOLDING CORPORATION Contract Liability (Deferred Revenue)

SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Contract Liability (Deferred Revenue) of $33.19 million as of 2021-12-31, per its 10-K filed 2023-03-07.

Discontinued › Balance Sheet › Liabilities › Liabilities, Current

us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-03-07

  • 2021-12-31: Contract with Customer, Liability, Current $33.19M.
  • 2021-09-30: Contract with Customer, Liability, Current $37.24M.
  • 2021-06-30: Contract with Customer, Liability, Current $42.71M.
  • 2021-03-31: Contract with Customer, Liability, Current $47.30M.
Period endContract with Customer, Liability, Current
2021-12-31$33.19M
10-K · filed 2023-03-07
2021-09-30$37.24M
10-Q · filed 2021-11-09
2021-06-30$42.71M
10-Q · filed 2021-08-10
2021-03-31$47.30M
10-Q · filed 2021-05-13
2020-12-31$18.82M
10-K · filed 2022-03-07
2020-09-30$16.71M
10-Q · filed 2020-11-09
2020-06-30$20.36M
10-Q · filed 2020-08-07
2020-03-31$16.27M
10-Q · filed 2020-05-07
2019-12-31$20.92M
10-K · filed 2021-03-09
2019-09-30$20.25M
10-Q · filed 2019-11-12
2019-06-30$23.52M
10-Q · filed 2019-08-14
2019-03-31$25.36M
10-Q · filed 2019-05-15
2018-12-31$20.21M
10-K · filed 2020-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
CG Oncology, Inc. (CGON)United States$6.095B-27.95
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29